Abstract
Patients with rare genetic diseases (RGD) experience a lengthy diagnostic odyssey, involving complex diagnostic testing pathways. Compared to standard genetic tests, whole exome sequencing (WES) has a higher diagnostic yield and has potential to decrease time to diagnosis which is important for patients with suspected RGD and their families. We estimated time-to-diagnosis and cost-effectiveness of WES at different points in the diagnostic pathway.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
